Synonyms: GS-5885 | GS5885 | Harvoni® (ledipasvir + sofosbuvir)
ledipasvir is an approved drug (EMA & FDA (2014))
Compound class:
Synthetic organic
Comment: Ledipasvir is an orally available, direct-acting inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex [1].
|
|
No information available. |
Summary of Clinical Use ![]() |
Ledipasvir is approved to treat chronic HCV infection, in fixed-dose combination with sofosbuvir. |
External links ![]() |
For extended ADME data see the following: Drugs.com European Medicines Agency (EMA) |